Results 231 to 240 of about 181,898 (305)

NIR‐II‐Trackable LYTACs Phyto‐Nanotheranostics for Source‐Microenvironment Dual‐Track ROS Regulation in Acute Gouty Arthritis

open access: yesAdvanced Science, EarlyView.
The TPR‐LYTACs nanomaterial offers a dual‐pathway strategy for precise gouty arthritis treatment by targeting and degrading the ROS‐producing enzyme NOX2 inside macrophages while its antioxidant core clears accumulated ROS outside. This “source inhibition and microenvironment scavenging” approach, guided by NIR‐II imaging, effectively controls local ...
Jian Zhang   +15 more
wiley   +1 more source

Giant Cell Tumor of the Sacrum: A Narrative Review of Management Challenges and Modalities. [PDF]

open access: yesHealthcare (Basel)
Alaseem A   +6 more
europepmc   +1 more source

Cholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Full androgen deprivation (FAD) induces paracrine cholesterol in prostate cancer that drives the polarization of cancer‐associated fibroblasts (CAFs) and subsequent elevated matrix stiffness. Matrix stiffness in turn potentiates tumor cell survival under FAD pressure via dual mechanotransductive activation of the IRE1α‐XBP1s stress‐response axis ...
Shaojie Liu   +20 more
wiley   +1 more source

Toward Nano‐Nutritional Medicine: A Remotely Activated Trans‐Vaccenic Acid‐Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy

open access: yesAdvanced Science, EarlyView.
Eutectic mixtures from trans‐vaccenic acid (TVA) and stearic acid, which served as phase‐change material to encapsulate IR780, forming NIR‐responsive nanoparticles. IR780@TVA LNPs induce photothermal therapy and initiate adaptive anti‐tumor immunity.
Kang Liu   +12 more
wiley   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz   +1 more
wiley   +1 more source

No difference in prognosis between atypical intradermal smooth muscle neoplasms and dermal leiomyosarcoma: Local recurrence, metastasis, and overall survival in a nationwide cohort of 423 patients

open access: yesJournal of the American Academy of Dermatology
Abebe, Kiya   +13 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy